Myriad Genetics (MYGN) Operating Leases (2019 - 2026)

Myriad Genetics (MYGN) has reported Operating Leases for 8 consecutive years, with $84.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases fell 3.78% year-over-year to $84.1 million; the TTM figure through Mar 2026 stood at $84.1 million (down 3.78% YoY), while the FY2025 annual figure was $83.0 million, down 5.57% from the prior year.
• Operating Leases rose to $84.1 million in Q1 2026 per MYGN's latest filing, from $83.0 million in the prior quarter.
• Across five years, Operating Leases topped out at $130.9 million in Q4 2022 and bottomed at $5.9 million in Q1 2023.
• Historically, Operating Leases has averaged $77.8 million across 5 years, with a median of $87.4 million in 2022.
• Annual changes were most pronounced in 2023 — Operating Leases sank 95.21% — and 2024, when it jumped 1498.31%.
• Myriad Genetics' Operating Leases stood at $130.9 million in 2022, then fell by 25.59% to $97.4 million in 2023, then retreated by 9.75% to $87.9 million in 2024, then decreased by 5.57% to $83.0 million in 2025, then climbed by 1.33% to $84.1 million in 2026.
• Business Quant data shows MYGN's Operating Leases at $84.1 million in Q1 2026, $83.0 million in Q4 2025, and $84.9 million in Q3 2025.